Mark Bachleda
2021
In 2021, Mark Bachleda earned a total compensation of $1.3M as Chief Commercial Officer at Galera Therapeutics.
Compensation breakdown
Non-Equity Incentive Plan | $33,855 |
---|---|
Option Awards | $1,141,675 |
Salary | $109,920 |
Other | $2,965 |
Total | $1,288,415 |
Bachleda received $1.1M in option awards, accounting for 89% of the total pay in 2021.
Bachleda also received $33.9K in non-equity incentive plan, $109.9K in salary and $3K in other compensation.
Rankings
In 2021, Mark Bachleda's compensation ranked 7,857th out of 12,415 executives tracked by ExecPay. In other words, Bachleda earned more than 36.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 7,857 out of 12,415 | 37th |
Division Manufacturing | 3,471 out of 5,508 | 37th |
Major group Chemicals And Allied Products | 1,542 out of 2,378 | 35th |
Industry group Drugs | 1,371 out of 2,099 | 35th |
Industry Pharmaceutical Preparations | 1,015 out of 1,549 | 35th |
Source: SEC filing on April 28, 2022.
Bachleda's colleagues
We found two more compensation records of executives who worked with Mark Bachleda at Galera Therapeutics in 2021.